MedTrace Logo

Intensified Treatment With Carfilzomib in Myeloma Patients Still PET-positive After First Line Treatment.

NCT03314636 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 53

Last updated 2025-08-08

No results posted yet for this study

Summary

A PET-CT will be performed on patients with myeloma after a standard first-line treatment. The PET-positive patients will receive 4 cycles of Carfilzomb-Revlimid-Dexamethason (KRd), before a new PET-CT will be performed.

Conditions

Interventions

DRUG

Carfilzomib

See in arm description

DRUG

Lenalidomide

See in arm description

DEVICE

PET-CT

See in arm description

DRUG

Dexamethasone

See in arm description

Sponsors & Collaborators

  • Nordic Myeloma Study Group

    collaborator OTHER

  • Oslo University Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-16
Primary Completion
2021-11-01
Completion
2026-11-01

Countries

  • Denmark
  • Norway
  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03314636 on ClinicalTrials.gov